TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01474785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human ghrelin
Description: 0.5-1 pmol/kg.min of human ghrelin administered by IV two times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low calorie diet
Description: standard very low calorie diet that is prescribed for all RYGB patients after their operation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic/Euglycemic Clamp
Description: Insulin and glucose infusions to measure glucose kinetics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic/Euglycemic Clamp
Description: Insulin and glucose infusions to measure glucose kinetics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic/Euglycemic Clamp
Description: Insulin and glucose infusions to measure glucose kinetics.
Study: NCT01552512

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutributter Program
Description: Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutributter Program
Description: Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Package
Description: The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Package
Description: The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
Study: NCT02310737

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sharp incision
Description: The fascia will be opened with a sharp scissors in cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blunt incision
Description: Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
Study: NCT01565408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
Study: NCT03167788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rejuvesol Solution
Description: The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
Study: NCT04364815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus standard preventive measures
Description: Hydroxychloroquine and standard preventive measures

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard preventive measures
Description: Placebo tablet plus standard preventive measures as defined by PGH-HICU
Study: NCT03542266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 Administration
Description: CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP Administration
Description: CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5
Study: NCT01637584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
Study: NCT02827344

Intervention type: BIOLOGICAL
Intervention: blood sample collection for CTC and MDSC analysis
Description: * Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry
Study: NCT02200926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loaded breathing training
Description: 7 days/weeks, for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unloaded breathing training
Description: 7 days/week, for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 7 days/week, for 8 weeks
Study: NCT00844831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg bid for 28 days
Study: NCT03821155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Specialized physical therapy aimed at restoring balance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Prednisolone
Study: NCT02366923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study: NCT00870441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00395304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + montelukast
Description: Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
Study: NCT03636880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief treatment for Insomnia
Description: This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
Study: NCT02366923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study: NCT01183429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3F8 and 13-cis-retinoic acid
Description: 3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
Study: NCT03823105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OHR Tracker and PulseWatch
Description: Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
Study: NCT03981744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg
Description: Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 6 mg/kg
Description: Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 90 mg
Description: Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
Study: NCT03329625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways Triple P
Description: Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
Study: NCT02605993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: All treatments were given as IV infusions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: All treatments were given as IV infusions.
Study: NCT02936869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-based monetary incentives
Study: NCT03799952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zoomers on the Go Exercise Program
Description: 60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
Study: NCT00335738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT02217514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 high dose
Study: NCT03636880

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Monitoring
Description: This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
Study: NCT01082341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization with P. vivax irradiated sporozoites
Description: Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization with P. vivax irradiated sporozoites
Description: Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization with P. vivax irradiated sporozoites
Description: Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials.
Study: NCT02815358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental Stabilization Exercises
Description: The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercises
Description: Home exercises include passive stretching and active mobilization of the spine.
Study: NCT00378612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher sirolimus eluting coronary stent
Description: Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
Study: NCT02413216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TicHelper
Description: TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet Based Resources
Description: The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
Study: NCT01445210

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous saphenous nerve block
Description: 0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
Study: NCT01203020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
Study: NCT02393248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Study: NCT04227067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM TENS
Description: A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
Study: NCT02239367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Decision Aid
Description: The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
Study: NCT01128881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Factor IX Concentrate (purified, virus-inactivated)
Description: Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
Study: NCT02677623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study: NCT00745290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 200 mg bupivacaine HCl

Intervention type: DRUG
Group type: OTHER
Intervention: SKY0402
Description: 600 mg SKY0402 (study drug).
Study: NCT03556670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Worker Health
Description: The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.